Abstract
Hospitals are more and more interconnected. Due to the constant specialisation of hospitals, patients often need to travel further for specific diagnosis or treatment. Once the operation or treatment is done, they go back to their own regional hospital. This increasing movement of patients heightens the risk of spreading of multiresistant microbes. To tackle this problem regionalisation of infection prevention, and close collaboration between medical institutions seems the way forward. The other key question treated in this chapter is the role of guidelines and protocols. Although nobody questions their importance and usefulness, they do create in some circumstances such complicated situations, that their rigidity raises questions. Some of the very resistant microorganisms have a rather low pathogenic character. But since they are classified as ‘very resistant’ the guidelines and protocols demand strict and expensive infection prevention measures. The question here is whether the costs of these measures do not outweigh their benefits. Finally, this is closely linked to the question of (mandatory) warning and reporting systems for outbreaks.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
For information about horizontal and vertical gene transfer, please refer to Chap. 2.
- 2.
Haematology is concerned with diseases or disorders of the blood, the bone marrow, the spleen or the lymphatic system.
- 3.
In cohort care, one group of patients is treated in isolation as a group.
- 4.
The Ems Dollart Region (EDR) comprises the Dutch provinces of Groningen, Friesland, Drenthe and Overijssel, and the north-western part of the German states of Lower Saxony and North Rhine-Westphalia.
- 5.
The VRE genotype in question is VanB. The VanB genetic type makes a bacterium resistant to vancomycin, but not teicoplanin. The VanA genotype causes resistance to both antibiotics. VanB VRE sometimes possesses a low level of resistance to vancomycin that cannot be identified by traditional testing methods. This leads to underdiagnosis and spread of resistance.
- 6.
Rob Willems presented the figures quoted here at the symposium ‘VRE Wat moet je ermee’ (‘VREs: what is their significance?’), which took place in Nijmegen on 4 October 2012.
- 7.
The prevalence of a condition describes the number of cases per 1000, 10,000 or 100,000 members of the population at a specific point in time.
- 8.
The government and parliament’s independent advisory body on questions of public health.
- 9.
Enterococcus is the name given to a group of bacteria of several types (species), e.g. Enterococcus faecalis or Enterococcus faecium. Enterococcus spp. is the designation given to the whole group, without specifying which species is intended. The double ‘p’ indicates the plural. Enterococcus sp. with one ‘p’, means that a single Enterococcus is being referred to, but it is not clear which type.
- 10.
Graphene consists of a single layer of carbon atoms.
- 11.
Gastroenterology is concerned with diseases of the gastrointestinal tract; nephrology is concerned with kidney diseases.
- 12.
ENT, ear, nose and throat.
- 13.
At the end of September 2012, VRE was once again diagnosed in some patients in the Isala Clinics. The conversation with Kluijtmans had already taken place by this time.
- 14.
This conversation with professor Dettenkofer took place late 2014.
- 15.
Linezolid and the new drug telavancin.
- 16.
European Antimicrobial Resistance Surveillance System.
- 17.
According to the annual ECDC figures, in 2013, 46.8% of all invasive S. aureus isolates in Portugal were MRSA. By 2019 it had decreased to 34.8%. In 2013, 23.3% of invasive isolates of Enterococcus faecium in Portugal were resistant to vancomycin. After a remarkable reduction in 2019 the number of invasive E. faecium isolates resistant to vancomycin in Portugal had decreased to 9% (ECDC Surveillance Atlas – Antimicrobial resistance 2020b).
- 18.
The University Medical Centre Groningen is the largest transplant centre in the Netherlands, and the only centre where transplants of all organs are carried out.
- 19.
Nonetheless, since the introduction of the Dutch Public Health Act on 1 December 2008, which replaced the infection legislation (among other things), an obligation to report MRSA infections has indeed existed.
- 20.
A report appears annually (NethMap) presenting data on the current use of antibiotics and the development of resistance in the Netherlands. In 2012, for the first time, this appeared simultaneously with the MARAN Report covering the veterinary sector. The Stichting Werkgroep Antibioticabeleid (SWAB) publishes the report annually in English.
References
Bhateja, P., Mathur, T., Pandya, M., et al. (2005). Detection of vancomycin resistant Staphylococcus aureus: A comparative study of three different phenotypic screening methods. Indian Journal of Medical Microbiology, 23(1), 52–55. Accessed from http://www.bioline.org.br/pdf?mb05012.
Bonten, M. J. M., Friedrich, A., Kluytmans, J. A. J. W., et al. (2014). Infectiepreventie in Nederlandse ziekenhuizen. Nederlands Tijdschrift voor Geneeskunde (NTVG), 158, A7395. Accessed from https://bit.ly/38oFt2K English abstract https://bit.ly/35ibrf2
Ciccolini, M., Donker, T., & Köck, R. (2013). Infection prevention in a connected world: The case for a regional approach. International Journal of Microbiology, 303(6-7), 380–387. https://doi.org/10.1016/j.ijmm.2013.02.003.
Cong, Y., Yang, S., & Rao, X. (2020). Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features. Journal of Advanced Research, 21, 169–176. https://doi.org/10.1016/j.jare.2019.10.005.
De Greef, S. C., Schoffelen, A. F., & Verduin, C. M. (2020). NethMap 2020: Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands in 2019/MARAN 2020: Monitoring of antimicrobial resistance and antibiotic usage in animals in the Netherlands in 2019. https://doi.org/10.21945/RIVM-2020-0065
De Vrieze, J. (2018). Antibioticaresistentie in Nederland. Alles uit de kast? Nederlands Tijdschrift voor Geneeskunde (NTvG), 162, C3994. Accessed from https://www.ntvg.nl/artikelen/antibioticaresistentie-nederland
Donker, T. (2014). Disease transmission through hospital networks. Thesis. Accessed November 12, 2020, from https://bit.ly/2Uniygq
Donker, T., Wallinga, J., & Grundmann, H. (2010). Patient referral patterns and the spread of hospital-acquired infections through National Health Care networks. PLoS Computational Biology. https://doi.org/10.1371/journal.pcbi.1000715.
Donker, T., Wallinga, J., Slack, R., et al. (2012). Hospital networks and the dispersal of hospital-acquired pathogens by patient transfer. PLoS One. https://doi.org/10.1371/journal.pone.0035002.
EARSS. (2009). EARSS Annual Report 2008. On-going surveillance of S. Pneumoniae, S. aureus, E. coli, E. faecium, E. faecalis, K. pneumoniae, P. aeruginosa. Accessed November 16, 2020, from https://bit.ly/2UtY6u3
ECDC (European Centre for Disease Prevention and Control). (2011). Updated ECDC risk assessment on the spread of New Delhi metallo-β-lactamase and its variants within Europe. https://doi.org/10.2900/14890. Accessed from https://bit.ly/39enL17
ECDC (European Centre for Disease Prevention and Control). (2020a). Additional tables EU/EEA population weighted mean 2019. Accessed January 7, 2021, from https://bit.ly/35jUHEa
ECDC (European Centre for Disease Prevention and Control). (2020b). Surveillance Atlas – Antimicrobial resistance; permanently updated. Accessed November 16, 2020, from https://bit.ly/38ozxq8
Endtz, H. P., Van den Braak, N., & Van Belkum, A. (1997). Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in The Netherlands. Journal of Clinical Microbiology, 35(12), 3026–3031. Accessed from https://bit.ly/398xt54.
Gezondheidsraad. (1998). Health Council of the Netherlands: Committee on Antimicrobial growth promotors. Antimicrobial growth promotors. In Dutch with English summary. Accessed November 14, 2020, from https://bit.ly/3ktZjwc
Hiramatsu, K. (2001). Vancomycin-resistant Staphylococcus aureus: A new model of antibiotic resistance. The Lancet Infectious Diseases, 1(3), 147–155. https://doi.org/10.1016/S1473-3099(01)00091-3.
Hiramatsu, K., Aritaka, N., Hanaki, H., et al. (1997). Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. The Lancet, 350(9092), 1670–1673. https://doi.org/10.1016/S0140-6736(97)07324-8.
Kest, H., & Kaushik, A. (2019). Vancomycin-resistant Staphylococcus aureus: Formidable threat or silence before the storm? Journal of Infectious Diseases and Epidemiology, 5(5). https://doi.org/10.23937/2474-3658/1510093.
Klare, I., Witte, W., Wendt, C., et al. (2012). Vancomycin-resistente Enterokokken (VRE). Bundesgesundheitsblatt, 55(11/12), 1387–1400. https://doi.org/10.1007/s00103-012-1564-6.
Leavis, H. L., Willems, R. J., & Mascini, E. M. (2004). Vancomycin resistant enterococci in the Netherlands (Abstract). Nederlands Tijdschrift voor Geneeskunde (NTvG), 148(18), 878–882. Accessed from https://bit.ly/35lcKtH.
Lemstra, W. (2012). Oog voor het onzichtbare (An eye for the invisible). Accessed November 16, 2020, in Dutch https://bit.ly/3hQF9g8 or in German https://bit.ly/3pYYIG4
Mascini, E. M., Bonten, M. J. M., Troelstra, A. et al. (2001). De melaatsen van de nieuwe eeuw. Medisch Contact. Accessed March 31, 2021, from https://www.medischcontact.nl/nieuws/laatste-nieuws/artikel/de-melaatsen-van-de-nieuwe-eeuw.htm
Melo-Christino, J., Resina, C., Manuel, V., et al. (2013). First case of infection with vancomycin-resistant Staphylococcus aureus in Europe. The Lancet, 382(9888), 205. https://doi.org/10.1016/S0140-6736(13)61219-2.
Mutters, N. T., Mersch-Sundermann, V., Mutters, R., et al. (2013). Kontrolle von Vancomycin-resistenten Enterokokken im Krankenhaus. Epidemiologischer Hintergrund und klinische Relevanz. In German. https://bit.ly/35BUxsp English abstract: Control of the spread of vancomycin-resistant enterococci in hospitals—Epidemiology and clinical relevance. Accessed from https://bit.ly/2LrnoYP
NOS. (2012). Video. Accessed November 12, 2020, from https://bit.ly/3i2YvyV
NVMM. (2015). Nederlandse Vereniging voor Medische Microbiologie - Dutch Society for Medical Microbiology. In Dutch. Accessed November 12, 2020, from https://bit.ly/3bfjPj1
PAHO/WHO. (2013). Pan American Health Organization/World Health Organization Epidemiological Alert: Vancomycin-resistant Staphylococcus aureus. Accessed November 16, 2020, from https://bit.ly/38odVdE
REMIS. (2018). Regionaal Microbiologisch-Infectiologisch Symposium (Regional microbiological and infectiological symposium). In Dutch. Accessed November 16, 2020, from https://www.remis-plus.net/over-remis/
Sagel, U., Schulte, B., & Heeg, P. (2008). Vancomycin-resistant enterococci outbreak, Germany, and calculation of outbreak start. Emerging Infectious Diseases, 14(2), 317–319. https://doi.org/10.3201/eid1402.070752.
SCAN. (1996). Report of the Scientific Committee for Animal Nutrition (SCAN) on the possible risk for humans of the use of avoparcin as feed additive. Opinion expressed 21 May 1996. Accessed November 14, 2020, from https://bit.ly/2LdVXBI
Schippers, E. I. (2016). Kamerbrief over voortgang aanpak antibioticaresistentie. In Dutch. Accessed November 12, 2020, from https://bit.ly/35mtPDY
Schulte, B., Heininger, A., & Authenrieth, I. B. (2008). Emergence of increasing linezolid-resistance in enterococci in a post-outbreak situation with vancomycin-resistant Enterococcus faecium. Epidemiology and Infection, 136(8), 1131–1133. https://doi.org/10.1017/S0950268807009508.
Sievert, D. M., Boulton, M. L., & Stoltman, G. (2002). Staphylococcus aureus resistant to Vancomycin – United States, 2002. Morbidity and Mortality Weekly Report (MMWR) of the Centers for Disease Control and Prevention (CDC), 51(26), 565–567. Accessed from https://bit.ly/2L2sg6V
Söderblom, T., Aspevall, O., & Erntell, M. (2010). Alarming spread of vancomycin resistant enterococci in Sweden since 2007. Eurosurveillance, 15(29). https://doi.org/10.2807/ese.15.29.19620-en.
Song, J. H., Hiramatsu, K., Suh, J. Y., et al. (2004). Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrobial Agents and Chemotherapy, 48(12), 4926–4928. https://doi.org/10.1128/AAC.48.12.4926-4928.2004. Accessed from https://aac.asm.org/content/48/12/4926.
SWAB – Stichting Werkgroep Antibioticabeleid. (2020). Nethmap/Maran annual reports. Accessed November 16, 2020, from https://swab.nl/nl/nethmap
Trakulsomboom, S., Danchaivaijitr, S., Rongrungruang, Y., et al. (2001). First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand. Journal of Clinical Microbiology, 39(2), 591–595. https://doi.org/10.1128/JCM.39.2.591-595.2001.
Van den Bogaard, A. E., Bruinsma, N., & Stobberingh, E. E. (2000). The effect of banning avoparcin on VRE carriage in The Netherlands. Journal of Antimicrobial Chemotherapy, 46(1), 146–148. https://doi.org/10.1093/jac/46.1.146.
Von Baum, H., Dettenkofer, M., Fahr, A.-M., et al. (2006). Konsensusempfehlung Baden-WĂ¼rttemberg. Umgang mit Patienten mit Glykopeptid-resistenten Enterokokken (GRE)/Vancomycin-resistenten Enterokokken (VRE). Hygiene & Medizin, 31(1/2), 30–32. Accessed from https://bit.ly/38M8jui.
WIP – Werkgroep Infectie Preventie Working Party on Infection Prevention. (2011, 2018). WIP-Richtlijn BRMO (Ziekenhuizen). In Dutch. Accessed November 14, 2020, from https://bit.ly/3s52qzN
WIP – Werkgroep Infectie Preventie Working Party on Infection Prevention. (2011, 2018). WIP-Richtlijn BRMO (VWK). In Dutch. Accessed November 14, 2020, from https://bit.ly/2LrqPyH
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
van den Brink, R. (2021). A Thin Layer of Faeces on Everything You Touch. In: The End of an Antibiotic Era. Springer, Cham. https://doi.org/10.1007/978-3-030-70723-1_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-70723-1_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-70722-4
Online ISBN: 978-3-030-70723-1
eBook Packages: MedicineMedicine (R0)